— Award of US$125,000 will support a second clinical site in Paris, France — Oxford, UK – 23 July 2012: Oxford BioMedica plc… Read More
— First patient treated at Cardiff University, Wales (UK) — Oxford, UK – 10 July 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company,… Read More
Click here to view the prospectus NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR… Read More
— Sanofi acquires exclusive worldwide rights to develop and commercialise StarGen™ and UshStat® — Oxford, UK – 29 June… Read More
Click here to read the full announcement THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT… Read More
— MHRA approval received to enable GMP manufacturing for clinical supply — Oxford, UK – 8 June 2012: Oxford BioMedica plc (“Oxford BioMedica”… Read More
Oxford, UK – 11 May 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 January to 10 May 2012. Read More
— Study meets primary endpoint: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function — Oxford, UK – 16 April 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
— Study meets primary endpoint: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function — Oxford, UK – 16 April 2012: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)… Read More
Click here to download the full 2011 preliminary results statement.Click here to download the 2011 results slide deck.Click here to listen to the… Read More
—Appointment of new Chief Financial Officer and Company Secretary — Oxford, UK – 10 February 2012: Oxford BioMedica (“Oxford BioMedica” or… Read More
— Positive review of all patient cohorts by Data Monitoring Committee —— ProSavin® provides long-term improvement of motor function —… Read More